Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
暂无分享,去创建一个
J. Leonard | C. Redfern | J. Gutheil | D. Gold | T. Guthrie | Mitchell R. Smith | J. Bender | P. Wiernik | J. Densmore | A. Bessudo | N. Janakiraman | R. L. Levy | W. Carter | P. Holman | R. Just | F. Rosenfelt | T. Melink
[1] G. Lichtenstein. Sargramostim for Active Crohn's Disease , 2006 .
[2] J. Timmerman,et al. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™ , 2005, Expert opinion on biological therapy.
[3] A. Hagenbeek,et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Levy,et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Kunkel. Idiotype Vaccines in the Treatment of B-Cell Non-Hodgkin's Lymphoma , 2004, Cancer investigation.
[6] J. Gribben,et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma , 2002, British journal of haematology.
[7] D. Czerwinski,et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.
[8] L. Kwak,et al. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. , 2002, Haematologica.
[9] Craig W. Reynolds,et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.
[10] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] D. Czerwinski,et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial. , 1997, Blood.
[13] R. R. Granados,et al. A new insect cell line from Trichoplusia ni (BTI-Tn-5B1-4) susceptible to Trichoplusia ni single enveloped nuclear polyhedrosis virus , 1994 .
[14] R. Levy,et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.
[15] S. Horning,et al. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.
[16] H. Eisen,et al. Myeloma proteins as tumor-specific transplantation antigens. , 1972, Proceedings of the National Academy of Sciences of the United States of America.